Atsushi Igarashi

Kobe City Medical Center General Hospital

Papers

1

Total Citations

4

H-Index

1

About

Dr. Atsushi Igarashi is a leading urologic oncologist whose research focuses on optimizing treatment strategies for high-risk and very high-risk prostate cancer. His major contributions center on evaluating the efficacy and safety of neoadjuvant chemohormonal therapy prior to radical prostatectomy, with a particular emphasis on patient compliance and its impact on long-term outcomes. In his pivotal 2024 study, Dr. Igarashi demonstrated that dose compliance with a regimen combining degarelix acetate and low-dose estramustine phosphate is a significant predictor of biochemical recurrence in patients with very high-risk prostate cancer undergoing robot-assisted radical prostatectomy. This work, which has already garnered 4 citations, provides critical insights into personalized treatment intensification. By systematically analyzing a cohort of 187 patients, Dr. Igarashi has helped clarify the therapeutic window for neoadjuvant approaches, directly informing clinical decision-making for this challenging patient population. His research bridges the gap between pharmaceutical compliance and oncologic control, offering a practical framework for improving outcomes in aggressive prostate cancer.

Research Focus

Key Achievements

1
H-Index
1
Papers
4
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy
4 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 15
🏛 Institutions: Kobe City Medical Center General Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago